"Designing Growth Strategies is in our DNA"
Fabry’s disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha-galactosidase enzyme leading to progressive organ dysfunction. Fabry’s disease is caused due to the abnormal accumulation of a specific fatty matter called globotriaosylceramide in multiple tissues of the body, including skin, eyes, brain, kidney, gastrointestinal system, heart, and central nervous system.
According to the U.S. National Library of Medicine, Fabry’s disease affects an estimated 1 in 40,000 to 60,000 males. Patients with Fabry’s disease suffer from severe pain of extremities, heart disorder, kidney failure, disabling gastrointestinal symptoms and stroke.
To gain extensive insights into the market, Request for Customization
Increasing prevalence Fabry's diseases coupled with increased adoption of novel therapies such as chaperone treatment is one of the major driving factors for the growth of the global Fabry's disease treatment market. Additionally, extensive R&D activities and potential approval of promising pipeline products, including enzyme replacement therapies and substrate reduction therapies are projected to escalate the growth of the global Fabry’s disease treatment market during the forecast period.
Side effects associated with the treatment options and lack of diagnostic resources in emerging countries leading to a lower rate of diagnosis in these countries are some of the factors restraining the growth of the global Fabry's disease treatment market.
Some of the major companies that are present in the global Fabry's disease treatment market is Genzyme Corporation, Shire, Amicus Therapeutics, Inc., ISU ABXIS, JCR Pharmaceuticals Co., Ltd., Protalix, Idorsia Pharmaceuticals Ltd, AVROBIO, Inc., Biosidus S.A., Neuraltus Pharmaceuticals, Inc., and others.
· Enzyme Replacement Therapy (ERT)
· Substrate Reduction Therapy (SRT)
· Chaperone Treatment
By Route of Administration
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
In 2018, among treatment, enzyme replacement therapy dominated the global Fabry's disease treatment market due to the massive sales of Fabrazyme and Replagal and approvals of promising pipeline candidates. This segment is projected to grow at comparatively higher CAGR during the forecast period.
North America dominated the global Fabry's disease treatment market in 2018. Increasing adoption of novel therapies and favorable reimbursement policies are some of the factors driving the growth of the Fabry's disease treatment market in the region. Also, favorable governmental policies encouraging pharmaceutical companies to increase research and developments investments in the field of rare diseases is anticipated to drive the growth of Fabry's disease treatment market in North America.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry